Understanding and targeting features of Myc-driven Osteosarcoma
Modeling and targeting intrinsic and extrinsic features of Myc-driven Osteosarcoma
['FUNDING_R01'] · EMORY UNIVERSITY · NIH-11049430
This study is looking at how certain genetic changes in Myc-driven osteosarcoma, a type of bone cancer that often affects kids, can impact how the tumor grows and responds to treatment, with the hope of finding better ways to help patients fight this tough disease.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | EMORY UNIVERSITY (nih funded) |
| Locations | 1 site (ATLANTA, UNITED STATES) |
| Trial ID | NIH-11049430 on ClinicalTrials.gov |
What this research studies
This research investigates the unique characteristics of Myc-driven osteosarcoma, a common bone tumor in children, particularly focusing on the genetic alterations associated with this cancer. The study aims to identify how these genetic changes affect the tumor's behavior and its interaction with the surrounding environment, which may influence treatment outcomes. By analyzing data from various sources and using advanced biological models, the research seeks to uncover potential therapeutic targets that could lead to more effective treatments for patients with this aggressive form of cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are pediatric patients diagnosed with osteosarcoma, particularly those with amplification of chromosome 8q24.
Not a fit: Patients with osteosarcoma who do not have the Myc amplification or those with other types of bone tumors may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new, targeted therapies that improve survival rates and reduce relapse in patients with Myc-amplified osteosarcoma.
How similar studies have performed: Previous research has shown promise in targeting oncogenes like Myc in other cancers, suggesting potential for success in this novel approach for osteosarcoma.
Where this research is happening
ATLANTA, UNITED STATES
- EMORY UNIVERSITY — ATLANTA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: YUSTEIN, JASON — EMORY UNIVERSITY
- Study coordinator: YUSTEIN, JASON
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Anti-Cancer Agents, anti-cancer drug